Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group

Cancer

Volumn 115, Issue 22, 2009, Pages 5339-5348

  Chou, Alexander J ^a   Kleinerman, Eugenie S ^b   Krailo, Mark D ^c,d   Chen, Zhengjia ^d   Betcher, Donna L ^e   Healey, John H ^a   Conrad III, Ernest U ^f   Nieder, Michael L ^g   Weiner, Michael A ^h   Wells, Robert J ^b   Womer, Richard B ⁱ   Meyers, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^h Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Children's Oncology Group; Metastatic osteosarcoma; Muramyl tripeptide; Survival

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; PHOSPHATIDYLETHANOLAMINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG MEGADOSE; FEMALE; HEARING; HEART RHYTHM; HUMAN; INFANT; INFECTION; LIVER TOXICITY; MALE; METASTASIS; NAUSEA AND VOMITING; NEPHROTOXICITY; OSTEOSARCOMA; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TREATMENT OUTCOME;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; INFANT, NEWBORN; MALE; NEOPLASM METASTASIS; OSTEOSARCOMA; PHOSPHATIDYLETHANOLAMINES; SURVIVAL ANALYSIS;

EID: 70449369314     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24566     Document Type: Article

References (27)

1. Seibel NL, Krailo M, Chen Z, et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. Cancer. 2007;109:1646-1653.
2. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-1161. (Pubitemid 43297356)
3. Daw NC, Billups CA, Rodriguez-Galindo C, et al. Metastatic osteosarcoma. Cancer. 2006;106:403-412.
4. McTiernan A, Meyer T, Michelagnoli MP, Lewis I, Whelan JS. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. Pediatr Blood Cancer. 2006;46:345-350. (Pubitemid 43201851)
5. Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome - the French pediatric experience. Cancer. 2005;104:1100-1109. (Pubitemid 41170240)
6. del Prever AB, Fagioli F, Berta M, Bertoni F, Ferrari S, Mercuri M. Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only. J Pediatr Hematol Oncol. 2005;27:42-45. (Pubitemid 40175961)
7. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011-2018.
8. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003;14:1126-1134.
9. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993;11:449-453. (Pubitemid 23071040)
10. Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol. 1993;14:286-292.
11. MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome- encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989;81:935-938.
12. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992;10:1310-1316.
13. Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993;62:101-107.
14. MacEwen EG, Kurzman ID, Helfand S, et al. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target. 1994;2:391-396.
15. Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995;9:927-938.
16. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995;18:93-99.
17. Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome- encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol. 1995;17:181-193.
18. Kurzman ID, Shi F, Vail DM, MacEwen EG. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm. 1999;14:121-128.
19. Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol. 2006;2:333-343. (Pubitemid 43960105)
20. Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep. 2006;8:310-315. (Pubitemid 43970983)
21. Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets. 2006;6:123-133.
22. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633-638.
23. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
24. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons; 1980.
25. Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol. 2003;25:840-841. (Pubitemid 37413831)
26. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452-2458. (Pubitemid 28309040)
27. Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488-494. (Pubitemid 36173693)